PPBTPURPLE BIOTECH LTD.

Nasdaq purple-biotech.com


$ 0.62 $ 0.06 (9.66 %)    

Wednesday, 27-Mar-2024 15:59:31 EDT
QQQ $ 443.93 $ -0.82 (-0.18 %)
DIA $ 397.72 $ 0.20 (0.05 %)
SPY $ 523.07 $ -0.10 (-0.02 %)
TLT $ 94.55 $ -0.08 (-0.08 %)
GLD $ 205.72 $ 2.62 (1.29 %)
$ 0.67
$ 0.61
$ 0.00 x 0
$ 0.67 x 100
$ 0.61 - $ 0.62
$ 0.53 - $ 2.16
99,151
na
16.91M
$ 1.06
$ 1.57
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 chardan-capital-maintains-buy-on-purple-biotech-maintains-11-price-target

Chardan Capital analyst Daniil Gataulin maintains Purple Biotech (NASDAQ:PPBT) with a Buy and maintains $11 price target.

 hc-wainwright--co-reiterates-buy-on-purple-biotech-maintains-10-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Purple Biotech (NASDAQ:PPBT) with a Buy and maintains $10 price target.

 purple-biotech-q4-eps-019-inline

Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.19) per share which met the analyst consensus estimate. This is a...

 hc-wainwright--co-reiterates-buy-on-purple-biotech-maintains-10-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Purple Biotech (NASDAQ:PPBT) with a Buy and maintains $10 price target.

 purple-biotech-says-determined-100mgkg-is-the-recommended-phase-2-dose-for-nt219-in-combination-with-cetuximab-in-the-treatment-of-head-and-neck-cancer-based-on-its-phase-12-dose-escalation-study

NT219 is a first-in-class small molecule dual inhibitor of IRS1/2 and STAT3. The Phase 1 dose escalation study is being conclud...

 why-green-giant-shares-are-trading-lower-by-around-37-here-are-20-stocks-moving-premarket

Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering. Gre...

 hc-wainwright--co-maintains-buy-on-purple-biotech-raises-price-target-to-10

HC Wainwright & Co. analyst Emily Bodnar maintains Purple Biotech (NASDAQ:PPBT) with a Buy and raises the price target f...

 purple-biotech-q3-eps-023-inline-159m-in-cash-cash-equivalents-and-short-term-deposits-in-october-2023-the-company-raised-an-additional-gross-amount-of-5m-extended-the-cash-runway-to-the-second-half-of-2025

Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.23) per share which met the analyst consensus estimate. This is a...

 purple-biotech-reports-positive-interim-and-preliminary-results-from-nt219-phase-12-study-in-rm-head--neck-cancer

Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developin...

 purple-biotech-to-present-new-cm24-pancreatic-cancer-biomarker-data-at-aacr-special-conference-on-september-28-2023

Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developin...

 hc-wainwright--co-maintains-buy-on-purple-biotech-raises-price-target-to-9

HC Wainwright & Co. analyst Emily Bodnar maintains Purple Biotech (NASDAQ:PPBT) with a Buy and raises the price target f...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION